重组人白介素-11与重组人促血小板生成素治疗化疗相关血小板减少的疗效比较

Comparison of Effect between rh IL-11 and rh TPO on Treatment for Lung Cancer Patients with Thrombocytopenia

目的比较重组人白细胞介素-11（rh IL-11）与重组人促血小板生成素（rh TPO）治疗肺癌患者化疗相关血小板减少症的临床疗效。方法采用回顾性分析法,收集2015年1月~2015年8月化疗导致血小板减少而使用rh IL-11或rh TPO的肺癌患者40例,比较两种药物治疗化疗相关血小板减少的疗效。结果 rh IL-11组、rh TPO组血小板开始恢复时间分别为4.79±3.87d和4.95±3.44d,达标时间分别为8.50±4.17d和8.81±4.26d,均无统计学差异（P值均〉0.05）;血小板升至100×109·L-1或较原水平上升50×109·L-1以上的患者,rh IL-11组有13例（68.42%）,rh TPO组为14例（66.67%）,均无统计学差异（P值均〉0.05）。结论 rh TPO和rh IL-11治疗化疗相关血小板减少的疗效无显著性差异。

OBJECTIVE To compare the clinical effect between rh IL-11 and rh TPO on treatment for lung cancer patients with thrombocytopenia. METHODS A retrospective analysis was uesd. Total 40 lung cancer patients who suffered thrombocytopenia caused by gemcitabine chemotherapy and treated with rh IL-11 or rh TPO from January2015 to August 2015 were involved in the study,and the efficacy were evaluated and compared. RESULTS The time of platelet count beginning to recover was 4. 79 ± 3. 87 d in rh IL-11 group and 4. 95 ± 3. 44 d in rh TPO group（ P〉0. 05）. The duration of thrombocytopenia was 8. 50 ± 4. 17 d in rh IL-11 group and 8. 81 ± 4. 26 d in rh TPO group（ P〉0. 05）. There were 13 patients in rh IL-11 group and 14 patients in rh TPO group whose platelet count increased above 100 × 109·L- 1or 50 × 109·L- 1more than previous level after therapy（ P〉0. 05）. CONCLUSION There was not differences between rh TPO and rh IL-11 on treatment for lung cancer patients with thrombocytopenia.